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 Introduction
   The use of pharmaceuticals, whether these are 
cold medicines sold at drugs stores or cancer drugs 
that cost hundreds of thousands of yen per ampule, 
provides us with great benefits, such as the treatment 
of sickness and the alleviation of symptoms. Though 
to the people who use them, it seems to be a given 
that such medicines are effective and without serious 
side effects, for the developers, it is difficult to develop 
such compounds, even with the latest scientific 
technology. 
   Figure 1 (a) shows the simplified process of 
normal drug development. Drug development starts 
with compound synthesis and optimization using 
knowledge from basic research, following which a 
few candidate compounds are selected by repeated 
test tube and animal experiments in the nonclinical 
test stages. Out of these candidate compounds, the 
ones that are estimated to possess the best qualities 
proceed to clinical trials, which is the stage in which 
the safety and efficacy of the compound on humans 
is verified. More than a few of them, however, cause 
unexpected side effects or show no effect on humans. 
As if to tease, “pharmaceutical companies have more 
than enough drugs, if you want to treat a lab rat,” it 
is very difficult to narrow down the results obtained 
in nonclinical studies to compounds that are safe and 
effective for humans, and more solid methods for 
doing this have been needed for a long time.
   Microdosing trials were proposed as an effective 
technique at the beginning of this century (Figure 
1(b)). Microdosing is a technique to narrow down 
the candidate compounds with the highest viability 
for clinical trials by administering them to humans 
at extremely low doses to examine their metabolism 
and tissue distribution when multiple candidate 
compounds remain after nonclinical trials. At these 
1
2
extremely low doses, there is a low risk of side effects, 
and therefore, this method enables the performance 
of candidate compounds in humans to be evaluated 
safely and in a short period of time. 
   This report introduces the trend of the microdosing 
technique in Japan and around the world in the 
context of recent drug development, and discusses 
the challenges facing the actual application of 
microdosing in the future. 
Problems with Drug Development 
a n d  t h e  S i g n i f i c a n c e  o f 
Microdosing
   The development of a new drug generally takes 
about 15 years and costs tens to hundreds of billion 
yen. Commonly sold and used drugs are created 
through an overwhelming process in which a single 
compound is selected from among hundreds of 
thousands of candidate compounds. Pharmaceutical 
companies usually take the main role in drug 
development, but currently, they rarely undertake 
all of the processes. In many cases, the evaluation of 
candidate compounds and clinical trials are referred to 
contract research organizations (CROs). CROs verify 
the safety and efficacy of candidate compounds by 
tests done in test tubes and with animals as nonclinical 
tests. 
   Animal experimentation is essential to today’s 
drug development. From the past to the present, a 
large number of animal studies have been conducted 
to obtain important data at the organism level that 
cannot be revealed by molecular and cellular tests. 
However, it is not a versatile method, since results 
vary due to species-specific differences between 
animals and humans. Figure 2 shows a comparison of 
bioavailability―the fraction of an orally administered 
dose of a drug that reaches systemic circulation and 
circulates in the body after the compound is absorbed 
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S C I E N C E  &  T E C H N O L O G Y  T R E N D S
Prepared by the STFC
Figure 1 :  The Drug Development Process
by the digestive tract―between humans and animals. 
Various drugs were tested in this experiment, and 
the results of each drug are plotted for comparison 
between humans and monkeys, humans and rodents, 
and humans and dogs. If the bioavailability of humans 
and the animals are proportional to each other, the 
results should plot along a linearly increasing line, 
whereas in reality, the plot points are scattered 
randomly. This means that there is little correlation 
between the bioavailability of humans and that of each 
animal, clarifying the difficulty of estimating human 
bioavailability from animal experiments.[1] 
   In drug development, several candidate compounds 
are selected in the nonclinical stage of the development 
and proceed to the clinical trials. As mentioned earlier, 
it is extremely difficult to select compounds in the 
nonclinical stages of development that will be safe 
and effective in humans, and the reality is that the 
probability of the compounds selected for clinical trials 
being approved as drugs in the end is low. Reasons for 
their disqualification vary; for example, the compound 
cannot be absorbed after oral administration and 
therefore does not reach circulation, it produces toxic 
metabolites when metabolized in the liver, it does 
not reach the target organ or tissue, it gets transferred 
to organs and tissues that trigger side effects, or it 
does not get metabolized in the body and actually 
exhibits toxicity. These are problems related to 
the pharmacokinetics, in other words, absorption, 
distribution, metabolism, and excretion, and take up 
a large proportion of the reasons for disqualification. 
Other factors contributing to disqualification include 
unwanted interactions with other drugs, as well as 
pharmacokinetics that vary from person to person or 
symptom to symptom. 
   Figure 3 shows the proportion of the compounds 
that make it to distribution out of the candidate 
compounds entering Phase I, the first stage, of clinical 
trials. Approximately 11% actually make it onto the 
market. When development is terminated at the level 
of clinical trials, various actions need to be taken, such 
as another set of clinical trials using other candidate 
compounds, and this is extremely inefficient, 
extending the development period and boosting up the 
costs.[2]
   If candidate compounds are disqualified for 
pharmacokinetic reasons, the success rate in clinical 
trials can be increased by selecting candidates based 
on their good pharmacokinetic properties in humans. 
This is how microdosing came along. Microdosing 
can reveal whether the candidate compounds’ 
metabolic rate is too fast or too slow, or if they reach 
the target organs or tissues in humans. If candidate 
compounds are selected with these data in mind, their 
viability will increase dramatically. In other words, 
improved viability means reducing losses from costs 
and time wasted on testing non-viable compounds, 
and as a result, reducing the development time. Of 
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1   はじめに
科学技術動向研究
医薬品開発技術の新展開
─マイクロド ズー臨床試験の技術と課題─
原田　良信
客員研究官
　ドラッグストアで購入できる風
邪薬から 1アンプル数十万円する
抗がん剤まで、我々は様々な医薬
品を使用することで、病気の治癒
や症状の緩和など、大きな恩恵に
与っている。使用者の立場からす
れば、医薬品は効果があって重大
な副作用がないのが当たり前であ
るが、研究開発側からすればその
ような化合物を開発することは極
めて難しく、現代の科学技術をもっ
てしても容易なことではない。
　図表 1（a）は、通常の医薬品の開
発過程を大まかに図示したもので
ある。医薬品の開発は、基礎研究
などから得た知見を出発点として
化合物の合成と最適化を行い、次
に非臨床試験として試験管内のテ
ストや動物実験を繰り返すことに
より、候補化合物を数個程度まで
絞り込む。これらの候補化合物の
中から最も性能が良いと“予測”さ
れるものが臨床試験、すなわちヒ
トにおける安全性と有効性の検証
過程に入るが、期待に反してヒト
では副作用を起こしたり効果が無
かったりする場合が少なくない。
「製薬企業にはマウスを治す薬なら
いくらでもある」と揶揄する言葉が
あるように、非臨床試験までの研
究結果からヒトに対して安全で有
効な化合物を絞り込むことは非常
に難しく、より確実性の高い方法
図表 1　医薬品の開発過程
科学技術動向研究センターにて作成
(a) The normal drug development process
(b) The drug development process using microdosing
Basic research 
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Review /
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course, microdosing also requires a certain amount 
of time and costs. However, both the costs and the 
time needed are slight compared to normal clinical 
trials, and considering the current viability of 11%, 
the overall time and cost for getting the drug onto 
the market can be drastically reduced (Figure 4). 
As shown here, microdosing has drawn attention 
as a technique to improve the efficiency of drug 
development. In addition, it is believed to be useful 
in allowing a company to find which of their drugs 
are candidates for having the highest sales among 
those with the same mechanisms of action (Best-in-
Class drugs), by comparing them with drugs that 
other companies have already come out with, and it is 
also said to be effective in allowing a company to re-
evaluate its own candidate compounds. 
The State of  the Japanese 
Pharmaceutical Industry
   Japan has contributed to a significant proportion of 
global drug development as one of the few countries 
that can develop new drugs domestically. At the same 
time, the country continues to move toward a “super-
aging” society, and with the most common cause of 
death being cancer, and with neuropsychiatric diseases 
such as dementia increasing rapidly, development 
of drugs to treat these illnesses is an urgent task. In 
addition, unmet medical needs, meaning medical 
needs with no existing effective treatments, must also 
医薬品開発技術の新展開─マイクロドーズ臨床試験の技術と課題─
11Science & Technology Trends   January  2011
2   医薬品開発の問題点とマイクロドーズ臨床試験を行う意味
　一般に、新規の医薬品を開発す
るには約 15 年の歳月と数百～ 1
千億円もの費用が必要と言われる。
数十万個の候補化合物の中から、
たった 1 つの化合物を選び出すと
いう、気の遠くなるような過程を
経て、一般に販売・使用される医
薬品が作り出されている。医薬品
は製薬企業が主体となって開発さ
れていくが、現在では全ての過程
を製薬企業が行うことは少なく、
候補化合物の評価や臨床試験は受
託試験実施機関（Contract Research 
Organization、以下 CRO と略す）
などに委託されることが多い。
CRO は、非臨床試験として、試験
管内でのテストや動物実験などに
より候補化合物の安全性や有効性
を確認する。
　動物実験は現在のところ医薬品
開発に不可欠な手法である。分子
や細胞レベルの実験ではわからな
い“個体”としての重要なデータを
提供し、古くから現在に至るまで
極めて多くの実験が行われている。
しかしながら、ヒトと動物におい
て反応の種差が大きく現れる場合
があり、万能な手法とは言えない。
図表 2 は、生物学的利用能、すな
わち医薬品が口から投与された後、
消化管において吸収され、体内を
循環する血流に到達する程度をヒ
トと動物で比較したものである。
この実験では、様々な薬物を使い、
ひとつひとつの薬物についてヒト
とサル・ヒトとげっ歯類・ヒトと
イヌを比較しプロットしている。
ヒトと動物の生物学的利用能があ
る程度比例するのであれば、各点
は右肩上がりの直線上付近に並ぶ
はずであるが、実際はほぼランダ
ムに散在している。つまり生物学
的利用能については、ヒトと各動
物間においてほとんど相関性は見
られず、動物実験からヒトのそれ
を予測することが相当に難しいこ
とを示している 1）。
　医薬品開発は、非臨床試験の段
階で候補化合物を数個程度までに
絞り込み、臨床試験に移行する。
前に述べたように、非臨床試験ま
での段階で、ヒトに対して安全で
有効な化合物を絞り込むことは非
常に難しく、臨床試験が開始され
たものが最終的に医薬品として承
認される確率は非常に低いのが現
状である。臨床試験で不適格とな
る理由は、例えば、飲んでも吸収
されず血中に移行しない、肝臓で
代謝されてその代謝物が毒性を持
つ、効果を発揮すべき臓器・組織
にたどり着かない、副作用を起こ
す臓器・組織に大量に移行する、
体内でほとんど代謝されずむしろ
毒性を発揮するなど、様々である。
これらはいわゆる薬物動態、すな
わち薬の吸収（absorption）・分布
（distribution）・代謝（metabolism）・
排泄（excretion）に関係する問題で、
化合物が医薬品として不適格にな
る理由の大きな部分を占めている。
また、他の医薬品との間で不要な
相互作用が起こる、個人間あるい
は病状による薬物動態の違いが大
きいことなども不適格要因になる。
　図表 3 は臨床試験の最初の段階、
すなわち第Ⅰ相臨床試験に入った
候補化合物のうち、どの程度の化
図表 2　生物学的利用能に関するヒトと動物の比較
参考文献1）を基に科学技術動向研究センターにて作成
が長く求められていた。
　有力な方法として 21 世紀になっ
て提唱されたのが『マイクロドーズ
臨床試験』である（図表 1（b））。マ
イクロドーズ臨床試験とは、非臨
床試験の段階で複数の候補化合物
が残って 1 つに絞り切ることがで
きない時に、極めて微量の候補化
合物をヒトに投与し、体内での代
謝や組織への移行性などをヒトで
検証し、臨床試験での成功確率の
高い候補化合物を選択しようとす
る方法である。投与する化合物の
量が微量のため、被験者に有害な
反応を起こさせる可能性は極めて
低く、安全にかつ短期間にヒト体
内における候補化合物の性能を評
価できる方法である。
　本レポートでは、近年の医薬品
開発の状況を踏まえつつ、日本と
世界のマイクロドーズ臨床試験の
技術動向と、マイクロドーズ臨床
試験の実施に向けた今後の課題に
ついて述べる。
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Figure 2 :  Comparison of bioavailability between human and animals
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合物が市販に至るかを示したもの
であるが、実際に市販される化合
物は 11％程度である。臨床試験で
開発が中止となれば、別な候補化
合物を使った臨床試験を再度行う
など、様々な対策を講ずる必要が
あり、極めて効率が悪く、開発期
間を長期化させ、開発コストを大
きく上昇させてしまう 2）。
　薬物動態に関係する事象で候補
化合物が不適格となるのであれば、
ヒトにおけ 特性の良い
候補を選べば、臨床試験での成功
確率も向上するはずである。そこ
で考えられたのが非臨床試験の段
階で行うマイクロドーズ臨床試験
である。マイクロドーズ臨床試験
を行うことにより、候補化合物の
代謝速度が早すぎたり遅すぎたり
していないか、効果を発揮してほ
しい臓器・組織に届いているかど
うかなどをヒトで明らかにするこ
とができる。そのデータを得た上
で候補化合物を選択し、確証を持っ
て臨床試験に移行すれば、成功確
率が飛躍的に向上する。成功確率
が向上することは、言い換えれば
“失敗して無駄となる臨床試験に注
ぎ込む費用と時間を減らす”ことで
あり、結果として開発コストを下
げ、また開発期間を短くすること
科学技術動向研究センターにて作成
図表 4　通常の臨床開発とマイクロドーズ臨床試験を活用した臨床開発
図表 3　米国製薬企業上位 10 社における医薬品開発の成功確率（1991 年～ 2000 年）
参考文献2）を基に科学技術動向研究センターにて作成
Produced at the STFC based on Reference[2]
Figure 3 :  Success rate of drug development in the top 10 U.S. pharmaceutical 
companies (1991–2000)
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be dealt with. 
   New drugs need to be developed; however, the 
number of new drugs developed in Japan has a 
decreasing tendency. Figure 5 shows the changes 
in the number of manufacturing approvals for new 
drugs, including those with new active ingredients, in 
Japan. This number starts to decrease in the later half 
of the 1990s, and it has notably not exceeded 10 per 
year after 2001.[3] A similar decrease can be observed 
in the U.S., albeit to a milder extent than in Japan.[4] 
In addition, the U.S. has increased its proportion of 
development of innovative drugs, meaning the first 
drug to be discovered that uses a certain mechanism (a 
new class of drug), whereas Japan has decreased here 
also.[5] 
   The decrease in the number of newly approved drugs 
causes the increase of development costs as a result. 
The average annual cost of research and development 
among 10 major pharmaceutical companies in Japan 
was 43.3 billion yen in 1999, whereas in 2008, it 
increased more than 3 times to 133 billion yen (Figure 
6). This caused development costs to exceed 20% of 
sales in 2008, and caused net profits to drop to 5%.[3] 
One of the biggest factors in these increasing costs is 
the low viability of compounds in clinical trials, as 
mentioned earlier. When development is terminated 
at the half way point, most of the costs invested up 
to that point are wasted, and the loss gets bigger as 
the termination occurs later on in the development. 
Consequently, it starts to appear as an increase in 
development costs for the company as a whole. 
   The United States is one of the biggest markets for 
Japanese pharmaceutical companies, and the country’s 
safety review of new drugs became stricter with the 
Food and Drug Administration (FDA) reform bill in 
2009. With this, development costs are expected to 
increase further with the increase that this has caused 
in the number of subjects and extended period that 
will be necessary in future clinical trials.[4] 
   Japan is one of the few countries that develop drugs 
domestically, as mentioned earlier, however, in the 
balance of trade, Japan has an excess of imports 
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図表 4　通常の臨床開発とマイクロドーズ臨床試験を活用した臨床開発
図表 3　米国製薬企業上位 10 社における医薬品開発の成功確率（1991 年～ 2000 年）
参考文献2）を基に科学技術動向研究センターにて作成
(a) Normal clinical development
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The clinical trials are done in order of priority, starting with candidate A. Candidates A, B, and C fail and candidate D finally succeeds.
(b) Clinical development using microdosing (MD tests)
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priority
No trials necessary
The order of priority is modified based on the results of MD testing, the clinical trials start from candidate D, and are successful. Clinical trials 
on candidates A, B, and C are not necessary.
Prepared at the STFC
Figure 4 :  Normal clinical development and clinical development using microdosing
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3   日本の医薬品産業のおかれた状況
　日本は、自国で新規の医薬品を
開発できる数少ない国として、世
界の医薬品開発の一角を占めてき
た。一方、超高齢化社会を迎えつ
つある日本では、がんが死亡原因
の第 1 位であり、認知症などの精
神神経疾患が急激に増加しており、
これらの疾患に対する治療薬の開
発が急務である。また、アンメッ
トメディカルニーズ（Unmet Medi-
cal Needs）、すなわち未だ有効な
治療法が無い医療ニーズにも引き
続き応えていかなければならない。
　新しい医薬品を次々に開発して
いくことが必要であるが、近年日
本発の新医薬品の数はむしろ減少
傾向にある。図表 5 は、日本にお
ける新有効成分を含む医薬品の製
造承認数の推移を示したものであ
る。1990 年代後半から減少傾向に
あり、特に 2001 年以降は 10 個未
満の状態が続いている 3）。米国に
おいても同様な減少傾向が見られ
るが、日本よりその度合いは低い 4）。
また、革新的な医薬品、すなわち
同じ作用機序の中で最初に発明さ
れた医薬品（New Class の医薬品）
や最も売上高の高い医薬品（Best in 
Class の医薬品）では、米国はその
割合を高めており、逆に日本はこ
れも減少しつつある 5）。
　新規に承認される医薬品の数が
減少することは、結果として研究
開発費の高騰にも大きく影響する。
日本の大手製薬企業 10 社の研究開
発費の平均は 1999 年には 433 億円
であったが、2008 年には 1,333 億
円となり、実に 3 倍以上も上昇し
た（図表 6）。これにより、2008 年
は売上高に対する研究開発費の割
合は 20％を超え、逆に純利益率は
5％台までに急落している 3）。研究
開発費の高騰の大きな要因のひと
つは、すでに述べた臨床試験にお
ける成功確率の低さにある。開発
途中で中止となった場合、それま
でに投資した費用のほとんどが無
駄となり、また開発期間の後期に
なればなるほど損失が大きくなる
など、結果として企業全体の研究
開発費の高騰として現れてくる。
　日本の製薬企業にとって米国は
最も大きな市場のひとつであるが、
2007 年 9 月の米国 FDA 改革法の
成立により、新薬の安全性に対す
る審査が厳格化された。これによ
り、今後臨床試験における被験者
数の増加や期間の延長を招くと予
想されており、いっそうの開発費
高騰が予想されている 4）。
　日本は、自国で医薬品開発がで
きる数少ない国のひとつであるこ
とはすでに述べたが、貿易収支上
では医薬品産業は輸入超過となっ
ている。2000 年と 2008 年を比較
すると、輸出は微増だが輸入は 2
倍近くまで増え、2008 年には輸出
額に対する輸入額が 3 倍を超え、
2008 年の収支は実に 7600 億円の
赤字である 6）。今後、日本は超高
齢化社会を迎えようとしており、
ますます国民医療費の高騰が予測
される。日本において多くの医薬
品を開発していくことは、国民に
大きな福音を与えるだけでなく、
純国産の医薬品の割合を増やして
いくことが、貿易収支の面からも
望ましいことがわかる。しかしな
がら、新しい医薬品を創出してい
図表 5　日本における新有効成分含有医薬品の製造承認数
参考文献3）を基に科学技術動向研究センターにて作成
ができる。もちろんマイクロドー
ズ臨床試験には一定の期間と費用
が必要であり、その分を開発に上
乗せすることになるが、通常の臨
床試験に比べれば費用・期間とも
に軽微であり、成功確率が 11％と
言われる臨床試験の現状を考えれ
ば、医薬品を市場に出すまでのトー
タルとしての費用と時間は大幅に
削減できる（図表 4）。このように、
マイクロドーズ臨床試験は医薬品
開発の効率を飛躍的に高める方法
として注目を集めている。さらに
マイクロドーズ臨床試験は、他社
が先行して発売している医薬品と
比較することによって同じ作用機
序の中で最も売上高の高い医薬品
（Best in Class の医薬品）候補を探索
したり、自社の候補化合物を再評
価するうえでも有効であると言わ
れている。
As of the end of December 2008
Number
Year
Prepared at the STFC based on Reference[3] 
Figure 5 :  Number of manufacturing approvals of drugs with new effective contents in 
Japan
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くという意味で、日本企業は非常
に不利な状況にある。日本の製薬
企業は世界的に見ればいずれも規
模が小さく、医薬品売上高で国内
業界第 1 位の武田薬品工業でも世
界の中では 17 位に留まる 7）。欧米
のメガファーマであれば豊富な資
金力を背景に、臨床試験を次々に
行うことも可能かもしれない。し
かしながら、規模の小さい日本の
製薬企業は、マイクロドーズ臨床
試験を実施するなど、より効率的
な医薬品開発を行って対抗すべき
であろう。
4   マイクロドーズ臨床試験の提唱と国際的なガイドラインの制定
　医薬品開発における成功確率の
低迷と研究開発費の高騰は、日本
の製薬企業に特有のものではなく、
世界的な問題である。そこで考え
られた問題解決のひとつの方法が、
マイクロドーズ臨床試験である。
　マイクロドーズ臨床試験の概念
が最初に示されたのは、2003 年の
欧州医薬品庁（EMEA）の方針説明
書（position paper）である。また、
2004 年 に は 米 国 食 品 医 薬 品 局
（FDA）が Critical Path 報告書を公
表し、通常の臨床試験に入る前に
探索的な臨床試験を行うことの重
要性を示した。さらに発展させた
考え方がその後も示され、これら
の動向を受けて、遅れてはいたが、
日本でも 2008 年 6 月に ｢ マイクロ
ドーズ臨床試験の実施に関するガ
イダンス ｣ が厚生労働省から示さ
れた。医薬品開発に関する規制（ガ
イドライン）は国際的に統一される
ことで、より効率的な医薬品開発
が行える。このため、2009 年 6 月、
日米 EU 医薬品規制調和国際会議
（ICH）のガイドラインである ｢ 臨
床試験の実施に必要とされる非臨
床安全性試験 ｣ の改訂版が、EU・
米国・日本の三極で合意され、
2010 年 2 月に日本国内に通知され
図表 6　日本の製薬企業大手 10 社の研究開発費と利益の対売上高比率の推移
参考文献3）を基に科学技術動向研究センターにて作成
Research and development costs per company 
(average of 10 companies)
Percentage of research and development 
(against sales)
Percentage of net profits (against sales)
100 million yen
100 million 
yen
Year
Prepared at the STFC based on Reference[3]
Figure 6 :  Changes in research and development costs and the proportion of profit over sales at 10 major 
pharmaceutical companies in Japan
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over exports on the pharmaceutical industry. When 
comparing 2000 and 2008, exports increased slightly, 
whereas imports almost doubled, making imports 
more than triple of exports in 2008, and creating a 
deficit of 780 billion yen in the 2008 balance.[6] Japan 
is moving toward a super-aging society, and further 
increases in medical costs are expected. Developing 
drugs in Japan not only benefits its citizens, but also 
helps the trade balance by increasing proportion of 
purely domestic drugs. However, Japanese companies 
are at a disadvantage in innovating new drugs. They 
are relatively small companies by global standards, 
as evidenced by Takeda Pharmaceutical, which has 
the highest domestic drug sales, and is ranked only 
17th in the world.[7] Mega-pharmaceutical companies 
in the U.S. and Europe may be able to run clinical 
trials one after another with their abundant financial 
resources. Small-scale pharmaceutical companies 
in Japan, therefore, should be more efficient in drug 
development, such as through the use of microdosing, 
to compete with these mega companies. 
Advocacy of Microdosing and 
International Guidelines
 
   Low viability and increases in development costs 
are not unique to drug development by Japanese 
pharmaceutical companies, but are, in fact, a global 
problem. One of the methods to solve this problem is 
microdosing. 
   The concept of microdosing first appeared in 
the position paper of the European Medicines 
Agency (EMEA) in 2003. In addition, the FDA 
issued a Critical Path Report in 2004, indicating the 
importance of conducting exploratory clinical trials 
before normal clinical trials, and further developing 
this idea later on. In response, though delayed, the 
MHLW (Ministry of Health, Labour and Welfare) 
in Japan released its Guidance on Microdosing in 
June 2008. Guidelines on drug development allow 
for more efficient development when standardized 
internationally. Therefore, the Non-clinical Safety 
Studies for the Conduct of Human Clinical Trials 
guideline of the International Conference on 
Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH), 
was revised and agreed upon among the EU, the U.S., 
and Japan, and publicized domestically in February 
2010.[8] This has provided a way for microdosing to 
be conducted based on internationally standardized 
guidelines. 
   The Guidance on Microdosing, in addition 
to prescribing technical guidelines such as the 
administering dose of the compound, toxicity tests on 
the compound, the compound quality, measurement 
methods, and evaluation of internal exposure, also 
prescribes the formation of protocol for the clinical 
trials, formation of a review board, and the notification 
of the relevant government agencies, and requires that 
microdosing studies actually being conducted adhere 
to all of these guidelines, as well as the ethical aspects 
of such testing. 
Implementation of Microdosing 
Studies  and  Measurement 
Technology
   Microdosing studies are trials where less than 1/100 
of an effective dose totaling less than 100ug of a 
candidate compound is administered once or multiple 
times (up to 5 times) to humans. Since the dosage is 
so small, there is little risk of side effects even when 
studies are done on humans. In addition, the toxicity 
testing that is carried out on animals before these 
studies can be completed more easily and in a shorter 
time than before normal clinical trials. In actuality, 
CROs commissioned by pharmaceutical companies 
conduct these studies, by administering microdoses 
of candidate compounds to several healthy male 
subjects and taking measurements. For measurement, 
one method is usually selected from 3 major methods 
(Table 1). 
5-1 Accelerator Mass Spectrometry (AMS)
   Accelerator mass spectrometry (AMS) is a method 
used for dating, and has a characteristic high 
sensitivity. In microdosing, candidate compounds are 
labeled with 14C. After administering a microdose of 
labeled compound to a human subject, samples such 
as blood, urine, and feces are analyzed using AMS. 
Since 14C-labeled compounds are administered, a 
small amount of radiation is released. The amount, 
however, is much less than the annual exposure to 
natural radiation, thus the radiation from the study 
is believed to have no effect on the subjects’ health, 
and the labeled compounds are not legally regarded 
as radioactive isotopes due to their small doses. It 
is useful for investigating how the compound is 
4
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absorbed, metabolized and excreted as a whole. In 
other words, by measuring the concentration of the 
administered candidate compound in the blood, urine, 
and feces chronologically, the pharmacokinetics of 
the candidate compound, as well as its metabolites in 
the human body, can be found. Since drugs become 
active and consequently act as drugs after becoming 
metabolized in the body in many cases, a low 
concentration of active metabolite in the measurement 
causes the compound to be given a low evaluation. 
In addition, the use of 14C labeled compound 
enables the discovery and/or identification of new 
metabolites, allowing for a separate toxicity test of the 
metabolite later. Since there is a difference between 
some metabolic enzymes in humans and in animals, 
there is a possibility that a metabolite that is toxic 
specifically in humans may form. If the strong toxicity 
is revealed beforehand, the candidate compound can 
be eliminated from the list, and wasteful clinical trials 
can be prevented. 
   Highly sensitive AMS analytic methods are already 
being used in the U.S. and Europe, and are applied 
to many microdosing trials. There are also private 
analytical companies that are equipped with AMS and 
possess high analytical techniques in Japan. 
5-2 Liquid Chromatograh Mass Spectrometers 
(LC/MS/MS)
   A liquid chromatograph mass spectrometer (LC/
MS/MS) is a device that combines a high-performance 
l iquid ch romatograph (HPLC) and a mass 
spectrometer (MS), and is able to quantify materials 
in a highly sensitive manner, as well as to detect blood 
concentrations of a drug at the order of pg/ml. As for 
its use in microdosing, it does not require labeling 
since it does not use radioactive isotopes. In addition, 
since it does not require a large facility, it can be used 
at a small scale organization or company. 
   One characteristic of LC/MS/MS is its effectiveness 
for cassette dose tests. The cassette dose test is a 
method to test multiple compounds simultaneously 
on one subject, enabling the comparison of the 
compounds under the same conditions, which 
provides valuable information that can not be obtained 
from the test of each compound. This means that it 
enables the compound with the best drug properties 
to be selected from multiple candidate compounds 
with similar expected effects, and also cuts costs by 
reducing the number of subjects required.
5-3 Positron Emission Tomography (PET)
   Positron emission tomography (PET) is a method 
that is commonly used for cancer diagnosis in 
medical institutions. It measures the distribution and 
chronological changes of gamma waves emitted by 
a radioactive tracer labeled with a positron emitting 
nuclide with a short half-life (11C, 13N, 18F, 15O, etc). 
In microdosing studies, the distribution and the 
concentration of the compound can be detected 
chronologically as imaging data by labeling the 
testing compound with a positron emitting nuclide 
and using it as the radioactive tracer. This is a 
superior characteristic particular to PET. The two 
methods introduced earlier can measure the time and 
concentration from the time of administration until its 
collection, however, they can not reveal the course the 
compound took. PET can show important information 
about whether a compound is transferred to the target 
organs or not. For example, there are more than a few 
examples of compounds targeting the brain that could 
not reach the human brain in clinical trials. This is due 
to the blood-brain barrier in the human brain, which 
blocks the unnecessary components of the blood from 
entering the brain. The use of PET enables it to be 
clearly seen whether a candidate compound reaches 
the brain, providing important information for the 
evaluation of the compound. In addition, PET enables 
the measurement of the occupancy of receptors 
Measuring method Labeling of testing material Characteristics
Accelerator Mass 
Spectrometry (AMS)
Radioactive isotopes with a 
long half life, such as 14C
*Extremely high sensitivity
*Capable of constructive analysis of the metabolites of the compound
*Requires large facilities and equipment
Liquid Chromatograh 
Mass Spectrometer 
(LC/MS/MS)
No labeling required *Capacity for profile prediction of the medicinal properties of a compound
*Suitable for cassette dose test
Positron Emission 
Tomography (PET)
Positron-emitting nuclide with a 
short half life, such as 11C, 13N, 
18F, 15O
*Capacity to measure distribution and concentration of the compound in the 
body
*Requires large facilities and equipment
Prepared at the STFC
Table 1 :  Measuring techniques used for microdosing
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(how much of the compound is bound to a particular 
receptor) that are involved in treatment or in side 
effects.
   As seen up to this point, PET has big advantages; 
however, it comes with disadvantages as well. Since 
PET uses radioactive isotopes, it requires strict 
management of the labeled compounds, necessitates 
assessments on the safety of the subjects’ exposure. 
In addition, it requires a large facility and equipment 
including cyclotron, automatic synthesizing apparatus, 
and PET scanner, requiring a big investment of several 
billion yen for its construction. In addition, there 
are some technical problems remaining, especially 
the existing difficulties with the efficient labeling 
techniques of candidate compounds with positron-
emitting nuclides in extremely short periods of time. 
In addition, since it is necessary to develop a synthetic 
method for labeling each individual compound, 
it is hoped that a universal synthetic method will 
be developed that can be applied to almost all 
compounds. 
Research Trends of Microdosing
   Microdosing is a relatively new method in the 
history of drug development, and its effectiveness 
had not been confirmed when it was first proposed. 
In particular, since the method involves taking 
measurements after very small doses of drugs are 
administered, there was no proof that measurements 
would be correlated (linear) to these when a 
therapeutic dose was administered, and this needed 
to be confirmed. In addition, many aspects of the 
measuring techniques were underdeveloped, and 
the establishment of a methodology, including the 
management of the overall study was necessary. 
Because of this, validation projects have been 
conducted to evaluate the effectiveness and problems 
of microdosing studies, using existing drugs whose 
safety and dosages have been confirmed in normal 
clinical trials, with England playing the central role. 
   One of the projects was the Consortium for 
Resourcing and Evaluation AMS Microdosing 
(CREAM) test conducted by four pharmaceutical 
companies led by a British CRO, Excelleron 
Corporation, in collaboration with Eli Lilly, Roche, and 
others, and its results were reported in 2006.[9] In this 
study, five existing drugs were used, out of which three 
maintained linearity, and two did not show enough 
linearity. However, it was determined that it was 
possible to predict the causes for disrupted linearity in 
the two samples using other information.[10] 
   Another project was the European Union Microdosing 
AMS Partnership Programme (EUMAPP), which 
began in January 2006 with the EU’s public support. In 
this study, the aforementioned Excelleron Corporation 
took charge of coordination, and nine EU private 
companies and members of academia participated in 
evaluating seven major compounds that had caused 
problems in animal studies. As a result, in a study 
in which microdoses of the target compounds were 
injected intravenously, the microdoses were confirmed 
to maintain linearity with the therapeutic doses. On 
the other hand, the data from oral administration did 
not maintain linearity to the same extent as it did with 
intravenous administration, however, they concluded 
that most of the causes for the disruption could be 
predicted by the compounds’ chemical properties.[11]
   These two research projects were groundbreaking 
in the sense that they clarified the effectiveness and 
problems of microdosing studies. In addition, by 
moving forward with these studies, the know-how for 
conducting microdosing was accumulated and human 
resources were trained in European CROs such as 
Excelleron Corporation. 
   A validation project for microdosing is being 
conducted in Japan also, namely, the NEDO project, 
which started in October 2008, entitled Development 
of Innovative Drugs Using Microdosing Studies: 
Based on the Quantificational Prediction Technology 
of Drug Properties and Efficacy. This project is more 
ambitious than those conducted in the UK or in 
Europe, as it aims to develop innovative technology 
that will support drug development, by fusing 
microdosing studies that use various measurement 
techniques, including molecular imaging by PET, 
with kinetic analysis methods related to the prediction 
of a compound’s dynamics in the body, dramatically 
improving the effectiveness and applicability of 
microdosing.[12] The abovementioned projects in the 
UK and the EU used only AMS, but this project 
values measurements by PET, as well as high-
performance LC/MS/MS. In addition, it is attempting 
to enable wider predictions to be made from the data 
obtained in microdosing studies, by combining test 
tube and animal experiment data, such as data on 
the drug transporters and metabolic enzymes that 
are involved in transporting a drug in and out of the 
6
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cell, and the influence of polymorphism on the genes 
related to them, and by constructing mathematical 
models from this combined data. The final results of 
the project are scheduled to be published in 2011, and 
they are expected to surpass those of the projects in 
Europe.[13]
Use of Microdosing Studies and 
the Status of CROs
   Corporate activity, particularly information on drug 
development by pharmaceutical companies, is rarely 
publicized, making it extremely difficult to grasp 
the overall picture of the microdosing studies being 
implemented. An investigation by the Pharmaceutical 
Research and Manufacturers of America (PhRMA) 
repor ted that in the nine par ticipating U.S. 
pharmaceutical companies they had surveyed, a total 
of 16 such studies had been implemented from 2006 
to 2007 and another 16 had taken place from 2008 
to 2009. However, it is noted that a larger number of 
such studies were actually being implemented.[14] In 
the UK, at first, many microdosing studies were being 
implemented for candidate compounds developed by 
startup companies, however, with the improvement 
of the measurement technology with PET and LC/
MS/MS, major pharmaceutical companies such as 
GlaxoSmithKline, Servier, Merck, Sanofi-Aventis, 
and Amgen, started to conduct these studies as well. 
Especially from 2009 to 2010, conditions changed 
dramatically, with some reporting that the number 
of commissioned microdosing studies had almost 
doubled.[14] 
   PET is one of the most powerful tools in 
microdosing, and with the recognition that imaging 
technology provides valuable information on the 
direction of drug development, GlaxoSmithKline 
founded a research institution, the Clinical Imaging 
Center, at Imperial College London’s Hammersmith 
Hospital in the UK, in 2008. This institution has 
two PET scanners and two MRI scanners, and 
has announced its use of imaging technology in 
approximately 40% of the drugs developed by the 
end of 2010.[15] As seen here, major pharmaceutical 
companies in the U.S. and Europe seem to be 
incorporating microdosing studies as a part of 
drug development. This is backed by the fact that 
the previously-mentioned validation studies on 
microdosing have provided training to the CROs, 
which makes it easier for the pharmaceutical 
companies to commission them.
   On the other hand, operational experience with 
microdosing in Japanese pharmaceutical companies 
is comparatively scarce, with few reports on this 
topic. Mid-sized Ono Pharmaceutical has reported 
to have commissioned a British CRO to implement 
microdosing studies, and decided to continue 
with development using the results it obtained on 
bioavailability. Astellas Pharma has applied the 
accumulated knowledge of many years of PET studies 
to found their own facility and research institution 
(Bioimaging Institute) with PET and MRI, and it is 
believed that it will start running microdosing trials.
   There are various CROs for different stages of drug 
development in Japan, creating a market of over 200 
billion yen, and their ability and quality are regarded 
as extremely high compared to CROs in the U.S. 
and Europe. They have traditionally evaluated the 
safety and properties of candidate compounds using 
animal experiments, however, in recent years, there 
is a movement to actively incorporate procedures that 
connect the animals and humans, with an increasing 
number of CROs conducting tests using human 
cells. Some of these CROs are participating in the 
abovementioned NEDO project, and though it is a 
validation project using existing drugs, it provides the 
opportunity to advance the know-how and training 
of human resources for running microdosing studies. 
In the future, when the use of microdosing gains 
momentum, the techniques for handling microdose 
compounds and metabolites will improve, and the 
CROs will mature to the level of Western CROs. 
Microdosing studies using PET are harder to tackle 
than those that use AMS and LC/MS/MS from the 
perspective of the facilities involved, meaning that 
only a portion of incorporated administrative agencies, 
universities, and corporations are able to use PET in 
reality. Because of this, those that cannot will need to 
collaborate with CROs to conduct studies using PET 
in the future.
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Problems with Microdosing 
Studies in Japan and Their 
Solutions
   We have discussed microdosing and its techniques, 
the state of drug development, and domestic and 
international companies and research trends. As a 
result of validation studies on micordosing in Europe, 
microdosing is believed to be a useful technique 
that will be used more in the future. In the U.S. 
and Europe, this technique has been taken on by 
both startup companies and major pharmaceutical 
companies, and is already being used for drug 
development. 
   On the other hand, though delayed from the 
European projects, the NEDO project has started 
in Japan. Pharmaceutical companies and CROs are 
participating in this project, learning measuring 
and analytical techniques and training personnel by 
actually conducting microdosing studies. However, 
Japanese pharmaceutical companies have yet to 
commission domestic CROs to conduct microdosing 
studies, and tend to commission CROs abroad for 
this. Though microdosing is not necessary for all 
drugs being developed, persistence of the current 
state will create a large gap in the efficiency of Japan’s 
drug development compared to the U.S. and Europe, 
causing a decline in the Japanese pharmaceutical 
industry. 
   To solve this, policies should be developed to 
construct a system for carrying out microdosing 
studies domestically based on the NEDO project 
results. Considering the validation projects that 
have already been implemented and the existence 
of experienced CROs in the U.S. and Europe, it is 
necessary to train human resources in domestic CROs 
with even higher techniques for microdosing studies 
to be conducted in Japan. Fortunately, domestic CROs 
are participating in the NEDO project, and higher 
levels of predictive techniques are starting to take 
shape under its ambitious goals. In order for Japanese 
pharmaceutical companies to commission domestic 
CROs rather than those abroad, these CROs need 
to accumulate experience. To do this, microdosing 
should be primed by the government (such as Ministry 
of Economy, Trade and Industry) by providing 
financial support to pharmaceutical companies to 
conduct microdosing studies, creating a virtuous 
circle in which pharmaceutical companies repeatedly 
commission CROs. Participating companies can 
be recruited publically, giving the opportunity 
for bioventures, universities, and incorporated 
administrative agencies, in addition to mid-sized 
pharmaceutical companies, to participate. Through 
this, pharmaceutical companies and CROs will receive 
actual experience with microdosing studies, resulting 
in the development of technology, personnel training, 
and upgrades in management ability, as well as the 
construction of a system for developing new drugs 
using microdosing within pharmaceutical companies. 
   In addition to the construction of a domestic system, 
it is also important to develop foundational technology, 
led by MEXT (Ministry of Education, Culture, Sports, 
Science and Technology). Microdosing is a barely 10-
year old method, and upgrading is needed in all areas, 
such as sampling and sample processing. Testing by 
PET, in particular, has extremely high potential as a 
molecular imaging technique for distinguishing tissue 
distribution as well as for determining the efficacy 
of future treatments. Since compound labeling is 
important in microdosing studies using PET, efficient 
labeling methods should be established in order to 
construct a domestic system that can respond to 
a large volume of demand. Since PET studies are 
more difficult in terms of the facilities required, it is 
desirable for NIRS (National Institute of Radiological 
Sciences) and RIKEN, which promote molecular 
imaging research, to provide the technology and 
facilities, and collaborate with CROs in implementing 
microdosing studies. 
   In recent years, many biomedicines such as antibody 
drugs, peptides, and nucleic acid drugs have appeared 
and increased in significance. The technology for 
testing these biomedicines by microdosing still needs 
to be established. 
   As mentioned earlier, drug development requires 
knowledge in various academic fields, and this has 
been one of Japan’s strong suits. In recent years, 
however, drugs in Japan are often introduced after 
their development abroad, creating concerns of the 
loss of substance in drug development in the country. 
If microdosing studies can be conducted outside of 
the country, more information on drug development 
will flow overseas, possibly worsening this situation. 
On the other hand, if a system through which 
microdosing studies can be conducted is established 
in Japan and uses better techniques than the U.S. and 
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Europe, pharmaceutical companies inside and outside 
of Japan will want to conduct their studies in Japan. 
Microdosing is a desirable tool for Japan to lead global 
drug development, and will allow many drugs to be 
developed efficiently to save people suffering from 
illness all over the world. 
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